133 related articles for article (PubMed ID: 16773846)
21. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K
Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
[TBL] [Abstract][Full Text] [Related]
22. Targeted therapies for non-small cell lung cancer.
Spicer J; Harper P
Int J Clin Pract; 2005 Sep; 59(9):1055-62. PubMed ID: 16115182
[TBL] [Abstract][Full Text] [Related]
23. Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
Chen WC; Chen W; Tseng GC; Lai HC; Shih CM; Hsia TC
Liver Int; 2010 Nov; 30(10):1548-9. PubMed ID: 20345702
[No Abstract] [Full Text] [Related]
24. [Current status of the study of the mechanism of epidermal growth factor receptor targeting drug therapy and their related markers].
Wang Y; Xu JM; Song ST
Zhonghua Zhong Liu Za Zhi; 2005 Sep; 27(9):573-6. PubMed ID: 16438862
[No Abstract] [Full Text] [Related]
25. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Sequist LV; Bell DW; Lynch TJ; Haber DA
J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
[TBL] [Abstract][Full Text] [Related]
26. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
27. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
Zhou CC; Deng XF
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
[No Abstract] [Full Text] [Related]
28. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A
Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444
[TBL] [Abstract][Full Text] [Related]
29. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
30. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
32. [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Shi YK
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):398-400. PubMed ID: 22883466
[No Abstract] [Full Text] [Related]
33. Are we expanding oligometastatic non-small-cell lung cancer using advanced radiotherapeutic modalities?
Jabbour SK
J Clin Oncol; 2014 Dec; 32(34):3794-6. PubMed ID: 25349298
[No Abstract] [Full Text] [Related]
34. Key questions for perioperative chemotherapy in resectable lung cancer: not pre vs post, but who and what?
Wakelee HA; Merritt R; Clément-Duchêne C
Oncology (Williston Park); 2009 May; 23(6):527, 532. PubMed ID: 19544694
[No Abstract] [Full Text] [Related]
35. Subdividing NSCLC: reflections on the past, present, and future of lung cancer therapy.
Argiris A; Gadgeel SM; Dacic S
Oncology (Williston Park); 2009 Nov; 23(13):1147-8, 1150. PubMed ID: 20043463
[No Abstract] [Full Text] [Related]
36. Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations.
Bhatt VR; Kedia S; Kessinger A; Ganti AK
J Clin Oncol; 2013 Sep; 31(25):3162-4. PubMed ID: 23897953
[No Abstract] [Full Text] [Related]
37. Treatment of Advanced Non-Small Cell Lung Cancer in 2018.
Doroshow DB; Herbst RS
JAMA Oncol; 2018 Apr; 4(4):569-570. PubMed ID: 29494728
[No Abstract] [Full Text] [Related]
38. Non-small-cell lung cancer: promising advances in treatment.
Quintyne KI; Walsh L; Coate L
Lancet Respir Med; 2013 Mar; 1(1):e13-4. PubMed ID: 24321810
[No Abstract] [Full Text] [Related]
39. Reply to v.R. Bhatt et Al and m.C. Chamberlain.
Welsh JW; McGovern SL; Wefel JS; Komaki R; Brown PD; Soh HE
J Clin Oncol; 2013 Sep; 31(25):3165-6. PubMed ID: 23943829
[No Abstract] [Full Text] [Related]
40. How Targeted Therapies Are Changing Treatment for Non-Small Cell Lung Cancer.
Becze E
ONS Connect; 2016 Feb; 31(2):24-5. PubMed ID: 26930998
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
